Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
5
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
merck
5
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
abbvie
bristol-myers squibb
deals
diagnostics
eli lilly
microbiome
novartis
pembrolizumab keytruda
pfizer
startups
What
drug
5
×
bio
roundup
new
approved
companies
fda
nash
news
acquisitions
advantages
approval
bar
biggest
biogen’s
biopharmaceutical
brings
build
buy
cancer
ceo
company’s
convo
daniel
debut
deeper
digital
disease
dna
dyne’s
earlier
epidemic
expect
failures
fatty
fingerprint
frenzied
gamble
genetic
gilead
Language
unset
Current search:
cancer
×
drug
×
merck
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues